No Detail Found!

Clinical Re-evaluation on Bioequivalence and Relative Bioavailability of Micronized Progesterone Hard Capsule (Yimaxin) and Micronized Progesterone Soft Capsule (Utrogestan) under Vaginal and Oral Administration Routes

Author(s)
Hanbi Wang Department of Obstetrics and Gynecology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College,National Clinical Research Center for Obstetric &Gynecologic Diseases,1# Shuai fu yuan,Dongcheng District,Beijing China.
Meizhi Liu Department of Obstetrics and Gynecology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College,National Clinical Research Center for Obstetric &Gynecologic Diseases,1# Shuai fu yuan,Dongcheng District,Beijing China.
Rui Chen Department of Obstetrics and Gynecology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College,National Clinical Research Center for Obstetric &Gynecologic Diseases,1# Shuai fu yuan,Dongcheng District,Beijing China.
Chengyan Deng Department of Obstetrics and Gynecology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College,National Clinical Research Center for Obstetric &Gynecologic Diseases,1# Shuai fu yuan,Dongcheng District,Beijing China.
Abstract
Background and Objective: To clinically re-evaluate relative bioavailability and bioequivalence of micronized progesterone (hard capsule) Yimaxin and micronized progesterone (soft capsule) Utrogestan under vaginal and oral administration routes. Methods: From December 2017 to June 2018, a total of 16 postmenopausal healthy women were recruited and received a total of four rounds of drug treatment with cross-over design, respectively Yimaxin and Utrogestan under vaginal and oral administration routes. Changes in the subjects' hormone levels after medication were monitored and an endometrial biopsy after a course of treatment was performed in our hospital. Result: The Geomeans of AUC0-t of Yimaxin and Utrogestan under vaginal administration route were 252.15 and 115.46, respectively, with a ratio of 2.19, and under oral administration route were 244.64 and 413.68, respectively, with a ratio of 0.59. The Geomeans of Cmax of Yimaxin and Utrogestan under vaginal administration route were 28.11 and 12.21, respectively, with a ratio of 2.30, and under oral administration route were 53.12 and 129.85, respectively, with a ratio of 0.41. Conclusion: Yimaxin was not bioequivalent to Utrogestan. Yimaxin had higher exposure to the drug in vivo at the same dose when administered vaginally, and Utrogestan had higher exposure to the drug in vivo at the same dose when administered orally.
Publication Details
Page(s) 1740-1746
DOI DOI not available
Published Journal: Pakistan Journal of Medical Sciences, Volume: 37, Issue: 7, Year: 2021

Request the full text from PASTIC

Keywords
Pharmacokinetics, Bioequivalence, Micronized progesterone hard capsule, Bioavailability, Micronized progesterone soft capsule
0

Citations

0

Downloads

83

Views